BCYC FY2025 EPS Estimate Lifted by Cantor Fitzgerald

Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for shares of Bicycle Therapeutics in a research report issued to clients and investors on Wednesday, February 26th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($3.49) per share for the year, up from their prior forecast of ($4.24). The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.06) per share.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $3.70 million for the quarter, compared to analysts' expectations of $5.47 million. During the same period in the prior year, the firm earned ($1.16) EPS. Bicycle Therapeutics's quarterly revenue was down 30.2% compared to the same quarter last year.

Several other equities research analysts also recently issued reports on BCYC. JMP Securities cut their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a report on Wednesday, December 18th. Stephens reissued an "equal weight" rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. B. Riley reduced their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. Needham & Company LLC reiterated a "buy" rating and set a $30.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Finally, HC Wainwright reissued a "buy" rating and set a $33.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $29.14.

Bicycle Therapeutics Trading Down 3.2 %

NASDAQ:BCYC traded down $0.33 on Friday, hitting $10.14. The company's stock had a trading volume of 462,573 shares, compared to its average volume of 302,289. Bicycle Therapeutics has a one year low of $10.07 and a one year high of $28.67. The stock has a fifty day moving average of $13.11 and a two-hundred day moving average of $19.19. The firm has a market capitalization of $700.13 million, a P/E ratio of -3.08 and a beta of 0.93.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of hedge funds have recently modified their holdings of the business. FMR LLC acquired a new stake in shares of Bicycle Therapeutics in the third quarter valued at about $3,406,000. The Manufacturers Life Insurance Company increased its position in shares of Bicycle Therapeutics by 33.2% during the third quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company's stock worth $2,935,000 after buying an additional 32,313 shares during the period. Principal Financial Group Inc. acquired a new stake in shares of Bicycle Therapeutics during the third quarter worth $10,028,000. State Street Corp lifted its holdings in Bicycle Therapeutics by 233.5% in the third quarter. State Street Corp now owns 86,271 shares of the company's stock valued at $1,952,000 after buying an additional 60,399 shares during the period. Finally, Jane Street Group LLC lifted its holdings in Bicycle Therapeutics by 35.7% in the third quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock valued at $457,000 after buying an additional 5,310 shares during the period. Institutional investors and hedge funds own 86.15% of the company's stock.

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker bought 985,397 shares of the company's stock in a transaction dated Friday, December 13th. The stock was purchased at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the acquisition, the director now owns 9,537,643 shares of the company's stock, valued at $131,237,967.68. The trade was a 11.52 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Travis Alvin Thompson sold 2,686 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the sale, the chief accounting officer now owns 32,146 shares in the company, valued at $482,190. This represents a 7.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,677 shares of company stock valued at $392,413 over the last quarter. 8.50% of the stock is owned by company insiders.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.